Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A new clinical research study at Roswell Park Cancer Institute(RPCI) will test a first-of-its-kind cancer ?vaccine? that may prove effective against many forms of solid-tumor cancers. The vaccine, to be investigated in a trial involving patients with brain cancer, generates an immune response that appears to put the target molecule, the cancer survival protein survivin, into a bind it can?t escape.
The peptide vaccine, developed at Roswell Park by Robert Fenstermaker, MD, and Michael Ciesielski, PhD, is based upon a specially engineered small protein molecule called a ?peptide mimic.? Dr. Fenstermaker is principal investigator of the phase I clinical research study, which will test the safety and immunological effects of the vaccine in patients with two types of brain cancer: glioblastoma multiforme (GBM) and anaplastic glioma. Called SurVaxM, the injectable vaccine will initially be given in four doses to nine patients.
http://www.bioresearchonline.com/do...cancer-vaccine-tested-roswell-park-study-0001
The peptide vaccine, developed at Roswell Park by Robert Fenstermaker, MD, and Michael Ciesielski, PhD, is based upon a specially engineered small protein molecule called a ?peptide mimic.? Dr. Fenstermaker is principal investigator of the phase I clinical research study, which will test the safety and immunological effects of the vaccine in patients with two types of brain cancer: glioblastoma multiforme (GBM) and anaplastic glioma. Called SurVaxM, the injectable vaccine will initially be given in four doses to nine patients.
http://www.bioresearchonline.com/do...cancer-vaccine-tested-roswell-park-study-0001